Equity MRK
Monday, July 23, 2018   
Adani Ports  384.05    (3.83%)
 
Asian Paints  1433.70    (2.63%)
 
Axis Bank  540.80    (1.19%)
 
Bajaj Auto  2689.10    (-5.35%)
 
Bharti Airtel  357.60    (3.49%)
 
Coal India  262.30    (-0.32%)
 
H D F C  1966.60    (-0.44%)
 
HDFC Bank  2157.75    (-1.48%)
 
Hero Motocorp  3163.90    (-6.20%)
 
Hind. Unilever  1686.60    (1.84%)
 
ICICI Bank  274.85    (3.33%)
 
IndusInd Bank  1938.90    (1.92%)
 
Infosys  1355.75    (0.55%)
 
ITC  283.85    (3.80%)
 
Kotak Mah. Ban...  1336.20    (0.21%)
 
Larsen & Toubr...  1279.50    (0.80%)
 
M & M  907.70    (-0.20%)
 
Maruti Suzuki  9697.15    (3.31%)
 
NTPC  158.15    (1.84%)
 
O N G C  156.50    (-0.86%)
 
Power Grid Cor...  176.95    (0.43%)
 
Reliance Inds.  1120.15    (-0.74%)
 
St Bk of India  266.40    (2.09%)
 
Sun Pharma.Ind...  561.40    (0.27%)
 
Tata Motors  258.25    (1.91%)
 
Tata Motors-DV...  142.00    (0.85%)
 
Tata Steel  516.85    (2.66%)
 
TCS  2005.05    (0.46%)
 
Vedanta  211.55    (4.42%)
 
Wipro  276.05    (-2.47%)
 
Yes Bank  387.55    (0.23%)
 
Market Menu
plusminDaily Market Tracker
plusminNews
Corporate Information
Corporate Actions
Other Markets
Close
You are here : Equity | News | Corporate News
Cadila Healthcare's JV facility of Zydus Hopsira Oncology receives EIR from USFDA
(13:08, 12 Jul 2018)
Cadila Healthcare announced that the manufacturing facility of Zydus Hopsira Oncology, a 50:50 joint venture company between Zydus Cadila and Hospira Inc., USA (now part of Pfizer Group) at Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA which concluded that the inspection is closed and states that theinspection classification of this facility is 'Voluntary Action Indicated' (VAI). The manufacturing plant had completed the USFDA audit from 5 to 12 April, 2018.

Powered by Capital Market - Live News